BioLineRx is trading 6.7% down at $1.95 in pre-market, with no clear company-specific announcement identified as the reason.
- The company’s investor-relations page lists an October 8 release as its latest press release.
- BioLineRx had announced an ESMO presentation scheduled for October 23–27, but available information does not establish it as the cause of the decline.
- Broader markets were under pressure, though the supplied index moves show no clear stock-specific link.